We are live on ! Find out more
TPST icon

Tempest Therapeutics
TPST

41 hedge funds and large institutions have $7.97M invested in Tempest Therapeutics in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% less funds holding

Funds holding: 50 → 41 (-9)

46% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 13

60% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 15

64% less capital invested

Capital invested by funds: $21.9M → $7.97M (-$14M)

Holders
41
Holders Change
-9
Holders Change %
-18%
% of All Funds
0.94%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
7
Reduced
13
Closed
15
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$884K
2
GC
GMT Capital
Georgia
+$821K
3
Wells Fargo
Wells Fargo
California
+$333K
4
VF
Virtu Financial
New York
+$129K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$114K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$5M
2
Jennison Associates
Jennison Associates
New York
-$3.06M
3
Deutsche Bank
Deutsche Bank
Germany
-$522K
4
LCM
Laurion Capital Management
New York
-$461K
5
BCM
BBT Capital Management
Texas
-$355K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$1.19M +$884K +295 +144%
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.07M +$15K +5 +1%
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$1.04M – – –
GC
4
GMT Capital
Georgia
$650K +$821K +274 New
Renaissance Technologies
5
Renaissance Technologies
New York
$533K -$126K -42 -16%
BC
6
Broadfin Capital
New York
$442K -$6K -2 -1%
Wells Fargo
7
Wells Fargo
California
$384K +$333K +111 +218%
BlackRock
8
BlackRock
New York
$371K -$6K -2 -1%
BCM
9
Bridgeway Capital Management
Texas
$324K – – –
TS
10
Third Security
Virginia
$303K – – –
Franklin Resources
11
Franklin Resources
California
$290K -$285K -95 -44%
Jacobs Levy Equity Management
12
Jacobs Levy Equity Management
New Jersey
$204K +$114K +38 +79%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$174K – – –
AIC
14
AWM Investment Company
New York
$122K – – –
VF
15
Virtu Financial
New York
$103K +$129K +43 New
D.E. Shaw & Co
16
D.E. Shaw & Co
New York
$100K -$123K -41 -49%
DMK
17
David M. Knott
$91K – – –
California Public Employees Retirement System
18
California Public Employees Retirement System
California
$80K +$74.9K +25 +278%
ERSOT
19
Employees Retirement System of Texas
Texas
$73K – – –
Millennium Management
20
Millennium Management
New York
$67K -$213K -71 -72%
Northern Trust
21
Northern Trust
Illinois
$56K -$3K -1 -4%
HCM
22
Howland Capital Management
Massachusetts
$51K – – –
WS
23
Wedbush Securities
California
$34K +$42K +14 New
Citadel Advisors
24
Citadel Advisors
Florida
$33K +$42K +14 New
OC
25
Oppenheimer & Co
New York
$31K -$3K -1 -7%
1
2 3

TPST Hedge Fund Activity: Q1 2018 in Review

41 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q1 2018, worth a combined $7.97M — down 64% from $21.9M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of TPST and 6 opened new positions — a net loss of 9 holders — while 13 trimmed existing stakes and 7 added.

The largest buyer was Sabby Management, adding an estimated $884K. The largest seller was Fidelity Investments, exiting entirely with an estimated $5M sold.

  • 41 institutional investors held Tempest Therapeutics (TPST) as of Q1 2018, down from 50 in Q4 2017.
  • Funds reported $7.97M of Tempest Therapeutics stock for Q1 2018, down 64% quarter-over-quarter.
  • 6 funds opened new Tempest Therapeutics positions in Q1 2018 and 15 closed out, a net change of -9 holders.
  • The largest Tempest Therapeutics buyer in Q1 2018 was Sabby Management, an estimated $884K added.
  • The largest Tempest Therapeutics seller in Q1 2018 was Fidelity Investments, an estimated $5M sold.

Based on aggregated 13F filings for Q1 2018.